Oscotec Plans US Trial For SYK Inhibitor Amid Failures By Others
This article was originally published in PharmAsia News
Executive Summary
South Korean drug developer Oscotec is planning to conduct early stage clinical trials in the US for its spleen tyrosine kinase inhibitor to treat rheumatoid arthritis. The company is betting that it will be able to license out the drug candidate, which is set to become a first-in-class therapy amid development failures by global competitors.